(Reuters) - Johnson & Johnson said an application to gain approval for a new usage of its prostate cancer cure Zytiga won a priority review status from U.S. health regulators, meaning that the drug would be reviewed faster than usual.https://mf.feeds.reuters.com/c/871/f/...2dbc2cd/mf.gif
https://da.feedsportal.com/r/13926364...2dbc2cd/a2.imghttps://pi.feedsportal.com/r/13926364...dbc2cd/a2t.img
More...
